← All organizations
Highest phase reached
Phase 4
First clinical trial
Jun 1, 2007First marketed drug
Apr 6, 2012First NDA
Apr 6, 2012Last known activity
Feb 28, 2023
Acquired by Eli Lilly on Nov 8, 2010
Timeline
2000s
- Jul 1, 2005
Avid Radiopharmaceuticals— Founded
2010s
- Nov 8, 2010
Eli Lilly— Acquired By
- Apr 6, 2012
florbetapir— NDA Organization
- Apr 6, 2012
florbetapir— NDA Secondary Org
2020s
- May 28, 2020
flortaucipir— Marketing Organization
Drugs by trial phase (11 distinct, 62 trials)
Phase 4 (1 own, 0 via acquisition)
Phase 3 (5 own, 0 via acquisition)
Phase 2 (1 own, 0 via acquisition)
Phase 1 (4 own, 0 via acquisition)
Indications
Studied for
- Alzheimer Disease
- Amyloidosis
- Aphasia, Primary Progressive
- Brain Diseases
- Brain Injuries
- Brain Injuries, Traumatic
- Chronic Traumatic Encephalopathy
- Cognition Disorders
- Cognitive Dysfunction
- Dementia
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Frontotemporal Dementia
- Lewy Body Disease
- Movement Disorders
- Neurodegenerative Diseases
- Parkinson Disease
- Parkinsonian Disorders
- Pick Disease of the Brain
- Supranuclear Palsy, Progressive
Marketed drugs (3)
Recent trials (50)
- NCT05775601Study directorEarly Phase 1Feb 28, 2023
- NCT05775601Lead sponsorEarly Phase 1Feb 28, 2023
- NCT04721756Study directorEarly Phase 1Oct 31, 2021
- NCT04721756Lead sponsorEarly Phase 1Oct 31, 2021
- NCT03901105Lead sponsorPhase 3Mar 28, 2019
- NCT03901105Study directorPhase 3Mar 28, 2019
- NCT03901092Study directorPhase 3Mar 26, 2019
- NCT03901092Lead sponsorPhase 3Mar 26, 2019
- NCT03467477Lead sponsorPhase 2Mar 8, 2018
- NCT03467477Study chairPhase 2Mar 8, 2018
- NCT03322462Lead sponsorPhase 2Oct 26, 2017
- NCT03322462Study chairPhase 2Oct 26, 2017
- NCT03040713Lead sponsorPhase 1Apr 11, 2017
- NCT03040713Study chairPhase 1Apr 11, 2017
- NCT03052972Lead sponsorPhase 1Mar 23, 2017
Details
- Founded
- Philadelphia, PA, US Jul 1, 2005
- First NDA
- Apr 6, 2012
- Last known activity
- Feb 28, 2023
Designations held
- Priority review